Izotropic Corporation’s (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging SystemNEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Izotropic Marks Breast Cancer Awareness Month by Highlighting Gaps in Care and the Need for IzoView Breast CTVANCOUVER, British Columbia, and SACRAMENTO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, marks Breast Cancer Awareness Month by underscoring the persistent limitations in current breast cancer imaging tools and the significant commercial and clinical opportunity for the Company’s flagship device, the IzoView Breast CT Imaging System.
Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) Stands Out with Proprietary Next-Gen Breast CT Imaging SystemNEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
AI in Breast Imaging: New BreastCT.com Article Examines IzoView’s Competitive EdgeVANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the publication of a new feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built for What Comes Next.”
Izotropic’s IzoView Breast CT the First in Category to Offer Patent-Pending Personalized Radiation Dose- Patent-pending pre-scan technology enables custom radiation dose tailored to patient’s unique breast size and composition -
Izotropic Publishes New FAQ Page for Investors, Analysts, and Healthcare Decision-MakersVANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of a new Frequently Asked Questions (“FAQ”) page on its corporate website.
Izotropic’s AI Breakthrough Positions IzoView to Redefine Breast CT Imaging Standards - Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT -
BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic’s IzoView DeviceVANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of BreastCT.com, a new online platform supporting the Company’s awareness initiatives.
Izotropic’s IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers- Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand
Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast ImagingVANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new podcast series. The first episode Beyond the Mammogram: Rethinking the Future of Breast Imaging is now available in English, Arabic, Chinese, French, German, Italian and Spanish.
Izotropic’s IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies- IzoView positioned to disrupt high-growth breast imaging markets with target device price of USD $500K
